Novartis Investigative Site

Frankfurt am Main 60590

0 studies enrolling now · 8 studies all time

What they study most

Arthritis, Psoriatic, Atherosclerosis, Cancer, Cardiovascular Disease and Lipoprotein(a), Metastatic Renal Cell Cancer, Neoplasms, Breast, Philadelphia Chromosome Positive CML, Rheumatoid Arthritis

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis — Completed
• A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients — Completed
• Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy — NO_LONGER_AVAILABLE